Leveraging its cross-border platform across the US, Europe and Asia, the Dechert capital markets group is well placed to advise on the full spectrum of public and private debt, equity, equity-linked and other securities offerings. The team is led by Boston-based Thomas Friedmann, Philadelphia-based Stephen M Leitzell, and Washington DC-based Harry Pangas. Pangas is recognised for his strength in negotiating, executing mergers, joint ventures and strategic transactions. Friedmann regularly advises alternative asset managers in their efforts to access permanent capital through Business Development Companies, closed-end funds and other vehicles. Leitzell advises on securities offerings, financings and public company governance matters. Rafe Khokhar departed in April 2025.
Legal 500 Editorial commentary
Accolades
Client satisfaction: Lawyer & team quality
Client satisfaction: Sector knowledge
Key clients
- Aquestive Therapeutics
- B&G Foods
- Bain Capital Specialty Finance
- BC Partners
- BioAtla
- Blackstone
- Business Development Company of America
- Diffusion Therapeutics
- EaglePoint Credit Company
- FS Investment Corporation
- Golub Capital BDC, Inc.
- Griffon Corporation
Work highlights
Represented FS KKR Capital Corp on the launch of its at-the-market offering, under which FSK may offer and sell up to $750 million of its common stock.
Advised French biotech company Abivax SA in connection with its $747.5 million public offering.
Represented Barings LLC as selling stockholder in connection with Accelerant Holding's $723 million initial public offering.
Practice head
Thomas Friedmann; Stephen Leitzell; Harry Pangas